{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-028205","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.301537+00:00","generated_at":"2026-06-01T07:19:40.669046+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Insmed prices $650M stock offering of 12.6M shares; net ~$713.9M","bullets":["Offering of 12,621,359 shares at $51.50/share; net proceeds to Insmed of ~$713.9M (incl. option exercise).","Underwriters exercised full 30-day option to purchase an additional 1,893,203 shares.","Proceeds to fund brensocatib R&D and pre-commercialization, ARIKAYCE commercialization, TPIP R&D.","Goldman Sachs, Leerink Partners, and J.P. Morgan are joint book-running managers; Morgan Stanley, Cantor, Stifel co-lead.","Offering expected to close May 31, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-028205","json":"https://secwatch.observer/filing/0001140361-24-028205.json","markdown":"https://secwatch.observer/filing/0001140361-24-028205.md","text":"https://secwatch.observer/filing/0001140361-24-028205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124028205/0001140361-24-028205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036124028205/ny20029730x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:19:40.669046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}